Literature DB >> 32870133

US as the Primary Imaging Modality in the Evaluation of Palpable Breast Masses in Breastfeeding Women, Including Those of Advanced Maternal Age.

Maggie Chung1, Jessica H Hayward1, Genevieve A Woodard1, Anna Knobel1, Heather I Greenwood1, Kimberly M Ray1, Bonnie N Joe1, Amie Y Lee1.   

Abstract

Background Women are increasingly delaying childbearing, and thus lactation, into their 30s and 40s, when mammography would typically be the initial imaging modality to evaluate palpable masses in the general population. Current guidelines recommend US as the first-line imaging modality for palpable masses in pregnant and lactating women, but data regarding breastfeeding women age 30 years and older are near nonexistent. Purpose To evaluate the diagnostic performance of targeted US as the primary imaging modality for the evaluation of palpable masses in lactating women, including those of advanced maternal age. Materials and Methods Lactating women with palpable breast masses evaluated at targeted US over a 17-year period (January 2000 to July 2017) were retrospectively identified. All US evaluations were performed at diagnostic evaluation, and mammography was performed at the discretion of the interpreting radiologist. Breast Imaging Reporting and Data System assessments, imaging, and pathology results were collected. Descriptive statistics and 2 × 2 contingency tables were assessed at the patient level. Results There were 167 women (mean age, 35 years ± 5 [standard deviation]), 101 of whom (60%) were of advanced maternal age (≥35 years). All women underwent targeted US, and 98 (59%) underwent mammography in addition to US. The frequency of malignancy was five of 167 (3.0%). Targeted US demonstrated a sensitivity and specificity of five of five (100%; 95% confidence interval [CI]: 48%, 100%) and 114 of 162 (70%; 95% CI: 63%, 77%), respectively. Negative predictive value, positive predictive value of an abnormal examination, and positive predictive value of biopsy were 114 of 114 (100%; 95% CI: 97%, 100%), five of 53 (9.4%; 95% CI: 3%, 21%), and five of 50 (10%; 95% CI: 3%, 22%), respectively. In the subset of 98 women who underwent mammography in addition to US, mammography depicted seven incidental suspicious findings, which lowered the specificity from 62 of 93 (67%; 95% CI: 56%, 76%) to 57 of 93 (61%; 95% CI: 51%, 71%) (P = .02). Conclusion Targeted US depicted all malignancies in lactating women with palpable masses. Adding mammography increased false-positive findings without any additional cancer diagnoses. © RSNA, 2020 See also the editorial by Newell in this issue.

Entities:  

Mesh:

Year:  2020        PMID: 32870133     DOI: 10.1148/radiol.2020201036

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams.

Authors:  Yiqiu Shen; Farah E Shamout; Jamie R Oliver; Jan Witowski; Kawshik Kannan; Jungkyu Park; Nan Wu; Connor Huddleston; Stacey Wolfson; Alexandra Millet; Robin Ehrenpreis; Divya Awal; Cathy Tyma; Naziya Samreen; Yiming Gao; Chloe Chhor; Stacey Gandhi; Cindy Lee; Sheila Kumari-Subaiya; Cindy Leonard; Reyhan Mohammed; Christopher Moczulski; Jaime Altabet; James Babb; Alana Lewin; Beatriu Reig; Linda Moy; Laura Heacock; Krzysztof J Geras
Journal:  Nat Commun       Date:  2021-09-24       Impact factor: 17.694

2.  A meta-analysis of accuracy and sensitivity of chest CT and RT-PCR in COVID-19 diagnosis.

Authors:  Fatemeh Khatami; Mohammad Saatchi; Seyed Saeed Tamehri Zadeh; Zahra Sadat Aghamir; Alireza Namazi Shabestari; Leonardo Oliveira Reis; Seyed Mohammad Kazem Aghamir
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

3.  Correlation between early features and prognosis of symptomatic COVID-19 discharged patients in Hunan, China.

Authors:  Yeyu Cai; Jiayi Liu; Haitao Yang; Taili Chen; Qizhi Yu; Juan Chen; Deng Huang; Zhu Chen; Quan-Liang Shang; Cong Ma; Xiangyu Chen; Enhua Xiao
Journal:  Sci Rep       Date:  2021-02-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.